DE69317436D1 - 1,4-benzothiazepine verwendbar als neurologische mittel - Google Patents

1,4-benzothiazepine verwendbar als neurologische mittel

Info

Publication number
DE69317436D1
DE69317436D1 DE69317436T DE69317436T DE69317436D1 DE 69317436 D1 DE69317436 D1 DE 69317436D1 DE 69317436 T DE69317436 T DE 69317436T DE 69317436 T DE69317436 T DE 69317436T DE 69317436 D1 DE69317436 D1 DE 69317436D1
Authority
DE
Germany
Prior art keywords
alkyl
optionally substituted
halo
phenyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69317436T
Other languages
English (en)
Other versions
DE69317436T2 (de
Inventor
John Rosindale Housley
James Edward Jeffery
Kenneth John Nichol
Bruce Jeremy Sargent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929223443A external-priority patent/GB9223443D0/en
Priority claimed from GB929223441A external-priority patent/GB9223441D0/en
Application filed by Knoll GmbH filed Critical Knoll GmbH
Application granted granted Critical
Publication of DE69317436D1 publication Critical patent/DE69317436D1/de
Publication of DE69317436T2 publication Critical patent/DE69317436T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69317436T 1992-11-09 1993-11-06 1,4-benzothiazepine verwendbar als neurologische mittel Expired - Fee Related DE69317436T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929223443A GB9223443D0 (en) 1992-11-09 1992-11-09 Therapeutic agents
GB929223441A GB9223441D0 (en) 1992-11-09 1992-11-09 Therapeutic agents
PCT/EP1993/003123 WO1994011360A1 (en) 1992-11-09 1993-11-06 1,4-benzothiazepines useful as neurological agents

Publications (2)

Publication Number Publication Date
DE69317436D1 true DE69317436D1 (de) 1998-04-16
DE69317436T2 DE69317436T2 (de) 1998-07-02

Family

ID=26301938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69317436T Expired - Fee Related DE69317436T2 (de) 1992-11-09 1993-11-06 1,4-benzothiazepine verwendbar als neurologische mittel

Country Status (22)

Country Link
US (1) US5580866A (de)
EP (1) EP0667866B1 (de)
JP (1) JPH08503202A (de)
KR (1) KR100313649B1 (de)
AT (1) ATE163927T1 (de)
BG (1) BG62519B1 (de)
BR (1) BR9307387A (de)
CA (1) CA2148584A1 (de)
CZ (1) CZ288595B6 (de)
DE (1) DE69317436T2 (de)
DK (1) DK0667866T3 (de)
ES (1) ES2113081T3 (de)
FI (1) FI952204A0 (de)
GR (1) GR3026386T3 (de)
HU (1) HUT71819A (de)
NO (1) NO304467B1 (de)
NZ (1) NZ257843A (de)
PL (1) PL179401B1 (de)
RU (1) RU2115650C1 (de)
SK (1) SK280522B6 (de)
UA (1) UA41342C2 (de)
WO (1) WO1994011360A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
PT100631B (pt) * 1991-06-28 1999-06-30 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogenio, seu uso e composicoes farmaceuticas que os contem
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
ZA9610853B (en) 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
GB9616279D0 (en) * 1996-08-02 1996-09-11 Knoll Ag Chemical process
PT864582E (pt) * 1997-03-14 2003-10-31 Aventis Pharma Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
ME01989B (me) 2008-03-03 2012-08-31 Servier Lab Postupak za proizvodnju benzotiazepina od gama-aminoalkilbenzena
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
EP2708535A1 (de) * 2012-05-11 2014-03-19 Les Laboratoires Servier Mittel zur Behandlung von Erkrankungen durch Modulation von Ryanodin-Rezeptoren
KR102157141B1 (ko) 2018-11-27 2020-09-17 주식회사 파미니티 으아리 추출물을 유효 성분으로 포함하는 인지 기능 개선용 조성물
KR102172916B1 (ko) 2018-12-07 2020-11-02 주식회사 파미니티 실크 펩타이드 및 천연 추출물을 포함하는 인지 기능 개선용 조성물
JP2023549583A (ja) * 2020-11-17 2023-11-27 アームゴ・ファーマ・インコーポレーテッド リアノジン受容体関連障害治療用薬剤
JP2024503045A (ja) 2021-01-08 2024-01-24 アームゴ・ファーマ・インコーポレーテッド リアノジン受容体調節因子の結晶形態およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362962A (en) * 1964-01-24 1968-01-09 Hoffmann La Roche Certain benzothiazepine derivatives
US3682962A (en) * 1970-03-17 1972-08-08 Sterling Drug Inc 1-substituted-1,2,3,5-tetrahydro-4,1-benzothiozepines
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
GB9111376D0 (en) * 1991-05-25 1991-07-17 Boots Co Plc Therapeutic agents
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Also Published As

Publication number Publication date
JPH08503202A (ja) 1996-04-09
NO304467B1 (no) 1998-12-21
FI952204A (fi) 1995-05-08
WO1994011360A1 (en) 1994-05-26
HUT71819A (en) 1996-02-28
GR3026386T3 (en) 1998-06-30
FI952204A0 (fi) 1995-05-08
NZ257843A (en) 1996-10-28
KR100313649B1 (ko) 2002-02-28
PL308757A1 (en) 1995-08-21
BR9307387A (pt) 1999-08-31
RU2115650C1 (ru) 1998-07-20
RU95112484A (ru) 1997-04-20
AU680639B2 (en) 1997-08-07
HU9501352D0 (en) 1995-06-28
NO951797L (no) 1995-05-24
SK280522B6 (sk) 2000-03-13
BG62519B1 (bg) 2000-01-31
CZ117695A3 (en) 1996-06-12
ES2113081T3 (es) 1998-04-16
US5580866A (en) 1996-12-03
DE69317436T2 (de) 1998-07-02
ATE163927T1 (de) 1998-03-15
PL179401B1 (pl) 2000-08-31
KR950704283A (ko) 1995-11-17
CZ288595B6 (cs) 2001-07-11
UA41342C2 (uk) 2001-09-17
EP0667866B1 (de) 1998-03-11
CA2148584A1 (en) 1994-05-26
BG99679A (bg) 1996-04-30
SK58895A3 (en) 1995-09-13
AU5464494A (en) 1994-06-08
EP0667866A1 (de) 1995-08-23
DK0667866T3 (da) 1998-05-25
NO951797D0 (no) 1995-05-08

Similar Documents

Publication Publication Date Title
DE69317436D1 (de) 1,4-benzothiazepine verwendbar als neurologische mittel
ATE225205T1 (de) Dispergiermittel
ATE168991T1 (de) Substituierte arylalkoxybenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
PL311811A1 (en) Arylopyrazoles as fungicides
ZA943241B (en) Therapeutic agents
ATE152442T1 (de) Substituierte arylalkylaminobenzyl- aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
ZA938302B (en) Therapeutic agents
JO1785B1 (en) Therapeutic agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee